Leerink Partners Maintains Outperform on Applied Therapeutics, Raises Price Target to $14
Portfolio Pulse from Benzinga Newsdesk
Leerink Partners has maintained an 'Outperform' rating on Applied Therapeutics (NASDAQ:APLT) and raised the price target from $11 to $14, indicating confidence in the company's future performance.
September 19, 2024 | 1:01 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Leerink Partners has increased its price target for Applied Therapeutics from $11 to $14 while maintaining an 'Outperform' rating, suggesting a positive outlook for the company's stock.
The increase in price target from $11 to $14 by Leerink Partners, along with the maintained 'Outperform' rating, indicates a strong positive sentiment from analysts. This is likely to boost investor confidence and potentially lead to a short-term increase in APLT's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100